SCHEMBL2484098

SCHEMBL2484098

O=[N+]([O-])c1ccc(N2C=NCN(c3ccc([N+](=O)[O-])cc3Cl)C2)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
GAA P10253 3/20 0.55
ALDH1A1 P00352 12/20 0.51
LMNA P02545 7/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
HPGD P15428 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MAPK1 P28482 2/20 0.48
HTT P42858 2/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PHGDH O43175 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6815260 0.75 GAA (0.69) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4137108 0.75 MAPT (0.63) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL6811691 0.74 GAA (0.71) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL28021548 0.73 ALDH1A1 (0.63) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL2544304 0.72 MAPT (0.50) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL2103553 0.72 ALDH1A1 (0.68) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL899512 0.72 ALDH1A1 (0.65) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL29793662 0.72 ALDH1A1 (0.65) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL2461666 0.72 ALDH1A1 (0.66) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL29937693 0.72 ALDH1A1 (0.68) MAPTGAAALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217022-B2 Analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for tumour treatment RUDJER BOSKOVIC INSTITUTE (HR) 2012-07-10 US disclosed
US-20110224412-A1 Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment RUDJER BOSKOVIC INSTITUTE (HR) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224412-A1 Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BAD MAPT 3013/4885GAA 209/4885ALDH1A1 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.